Jenkins Peter O, Turner Martin R, Jenkins Paul F
Guys and St Thomas' Hospital, London.
Clin Med (Lond). 2008 Jun;8(3):253-8. doi: 10.7861/clinmedicine.8-3-253.
The global burden of stroke, the undisputed success of intravenous thrombolysis in the management of myocardial infarction and subsequent evidence from animal models of cerebral infarction have all fuelled intense interest in the potential role for thrombolytic agents in the acute management of stroke in clinical practice. Before any clinical treatment is introduced universally its safety and efficacy must be demonstrated in the routine clinical environment and not just within the ideal conditions of controlled clinical trials. Similarly, the cost effectiveness of a new treatment modality is an essential consideration before its use is promulgated. This paper reviews the current scientific evidence for thrombolysis in stroke with reference to issues of safety, efficacy and cost effectiveness.
中风的全球负担、静脉溶栓治疗心肌梗死的无可争议的成功以及随后来自脑梗死动物模型的证据,都激发了人们对溶栓药物在临床实践中急性中风管理潜在作用的浓厚兴趣。在任何临床治疗被广泛应用之前,其安全性和有效性必须在常规临床环境中得到证明,而不仅仅是在对照临床试验的理想条件下。同样,在推广使用一种新的治疗方式之前,其成本效益也是一个重要的考虑因素。本文参考安全性、有效性和成本效益等问题,综述了目前关于中风溶栓治疗的科学证据。